Original Articles Open access

Does lymphoscintigraphy have a role in the diagnosis and management of lipedema?

Authors

Published
22 December 2025
Section
Original Articles
DOI
10.4081/vl.2025.14438

Abstract

Lipedema is a chronic and progressive connective tissue disorder characterized by symmetric accumulation of adipose tissue, predominantly in the lower limbs, often associated with pain, easy bruising, and reduced response to lifestyle interventions. Despite increasing recognition, the condition remains frequently misdiagnosed or mistaken for obesity or lymphedema. To investigate the role of lymphoscintigraphy in the diagnostic and therapeutic management of patients with clinically confirmed lipedema and assess its potential utility in detecting associated lymphostatic disorders. A retrospective observational study was conducted on 108 patients clinically diagnosed with lipedema between January 2019 and August 2023. Among them, 31 patients underwent lymphoscintigraphy due to suspected mixed pathology or surgical candidacy. Data on lymphatic involvement were collected and analyzed to determine correlations with clinical staging. In 58% of the selected cases, lymphoscintigraphy revealed no detectable lymphatic abnormalities. Of these, approximately 70% showed latent compensatory lymphatic patterns. The remaining 39% had confirmed alterations of the superficial and/or deep lymphatic system, suggesting a mixed clinical picture (lipo-lymphedema) with potential surgical contraindications. Lymphoscintigraphy is not essential for routine diagnosis of lipedema, which remains clinical. However, it is valuable in identifying cases with coexisting lymphostatic components and guiding surgical decisions. These findings support a multidisciplinary and individualized approach to diagnosis and treatment.

Keywords

References

  1. 1. Michelini S, Chiurazzi P, Marino V, et al. Aldo-Keto Reductase 1C1 (AKR1C1) as the first mutated gene in a family with nonsyndromic primary lipedema. Int J Mol Sci 2020;21:6264. DOI: https://doi.org/10.3390/ijms21176264
  2. 2. Priglinger E, Strohmeier K, Weigl M, et al. SVF-derived extracellular vesicles carry characteristic miRNAs in lipedema. Sci Rep 2020;10:7211. DOI: https://doi.org/10.1038/s41598-020-64215-w
  3. 3. Strohmeier K, Hofmann M, Jacak J, et al. Multi-level analysis of adipose tissue reveals the relevance of perivascular subpopulations and an increased endothelial permeability in early-stage lipedema. Biomedicines 2022;10:1163. DOI: https://doi.org/10.3390/biomedicines10051163
  4. 4. Hirsch T, Schleinitz J, Marshall M, Faerber G. Is the differential diagnosis of
  5. lipoedema by means of high-resolution ultrasonography possible? 2018. Available from: https://www.thieme-connect.de/products/ejournals/pdf/10.12687/phleb2431-4-2018.pdf?articleLanguage=en
  6. 5. Herbst KL, Hansen EA, Salinas LMC, et al. Survey outcomes of lipedema reduction surgery in the United States. PRS Glob Open 2021;9:e3807. DOI: https://doi.org/10.1097/GOX.0000000000003553
  7. 6. Wright TF, Herbst KL. Lymphatic injuries after suction lipectomy in women with lipedema. Am J Case Rep 2022;23:e935016. DOI: https://doi.org/10.12659/AJCR.935016
  8. 7. Brorson H, Corda D, Greco F, et al. Report of the Diagnosis Working Group. 2022. Available from: https://theila.net/wp-content/uploads/2024/09/pdf_news.pdf
  9. 8. Chakraborty A, Crescenzi R, Usman TA, et al. Indications of peripheral pain, dermal hypersensitivity, and neurogenic inflammation in patients with lipedema. Int J Mol Sci 2022;23:10313. DOI: https://doi.org/10.3390/ijms231810313
  10. 9. Grigoriadis D, Sackey E, Riches K, et al. Investigation of clinical characteristics and genome associations in the 'UK Lipoedema' cohort. PLoS One 2022;17:e0275889. DOI: https://doi.org/10.1371/journal.pone.0274867
  11. 10. von Atzigen J, Burger A, Grünherz L, et al. A comparative analysis to dissect the histological and molecular differences among lipedema, lipohypertrophy and secondary lymphedema. Int J Mol Sci 2023;24:7591. DOI: https://doi.org/10.3390/ijms24087591
  12. 11. Kruppa P, Gohlke S, Łapiński K, et al. Lipedema stage affects adipocyte hypertrophy, subcutaneous adipose tissue inflammation and interstitial fibrosis. Front Immunol 2023;14:1174208. DOI: https://doi.org/10.3389/fimmu.2023.1223264
  13. 12. Herbst KL, Kahn LA, Iker E, et al. Standard of care for lipedema in the United States. Phlebology 2021;36:779-96. DOI: https://doi.org/10.1177/02683555211015887
  14. 13. Hansdorfer-Korzon R, Czerwińska M, Teodorczyk J, Szamotulska J. Assessment of lipoedema awareness among Polish women: an online survey study. BMC Womens Health 2023;23:457. DOI: https://doi.org/10.1186/s12905-023-02614-7
  15. 14. International Consensus document. Lipoedema: a paradigm shift and consensus. J Wound Care 2020;29:S1-44. DOI: https://doi.org/10.12968/jowc.2020.29.Sup11b.1
  16. 15. Halk AB, Damstra RJ. First Dutch guidelines on lipedema using the international classification of functioning, disability and health. Phlebology 2017;32:152-9. DOI: https://doi.org/10.1177/0268355516639421
  17. 16. Herpertz U. Krankheitsspektrum des Lipödems an einer Lymphologischen Fachklinik - Erscheinungsformen, Mischbilder und Behandlungsmöglichkeiten. Vasomed 1997;5:301-7.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.